子分类：
| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 181 | ALKYD AND ARALKYD DERIVATIVES OF PHENOLIC POLYMERS | PCT/US9804121 | 1998-01-05 | WO9830596A3 | 1998-09-17 | HUTCHINGS DAVID A; HARIHARAN RAJAN; LUCAS EDWARD JR; ELAHI SYED A; RANDALL ALAN K; BOURLIER KENNETH |
| Phenolic aralkylation polymers modified by esterification with fatty acids, transesterification with glyceride oils, or other modifications to reactive hydroxyl moieties to improve the characteristics and properties of coating systems in which the modified materials are incorporated. At least a portion of the hydroxyl moieties of the polyol is esterified or otherwise modified. The hydroxyl moieties include those that have been "chain-extended", if desired. 00000 | ||||||
| 182 | HYDROPHOBIC ORGANIC LIQUID COMPOSITION FOR THE SELECTIVE EXTRACTION OF A LITHIUM SALT | PCT/IB2024051821 | 2024-02-26 | WO2024180451A3 | 2024-10-31 | DE SOUZA GUILLAUME; POUESSEL JACKY; GRASSOT JEAN-MARIE; LAURENCOT ADELINE; LOCHE JUSTINE; MABIRE DOMINIQUE |
| The present invention relates to a hydrophobic organic liquid composition for the selective extraction of a di-ionic lithium salt comprising a lithium cation and an anion complementary to the lithium cation, chosen in particular from Cl, I, Br, CN, MK and HCO 3, from a lithium-rich brine to be treated, said composition comprising (A) at least one compound extracting the lithium cation, chosen from the compounds of formula: (I) in which R1, R2, R3, R4, R5 and R6 are as defined in the description; (B) at least one organic, protic and hydrophobic compound solvating the anion complementary to the lithium cation; and (C) at least one hydrophobic polar organic diluent having a flash point at atmospheric pressure greater than 60°C, preferably greater than 75°C, more preferably greater than 90°C. | ||||||
| 183 | METHOD OF MANUFACTURING MOISTURE-CURE RESIN COMPOSITION | PCT/GB2023052700 | 2023-10-18 | WO2024094961A1 | 2024-05-10 | BARTHEL BERNARD |
| The present invention relates to a method of producing a moisture-cure resin composition, the method comprising the steps of: preparing a hydroxy alkyl urethane modifier having the formula:(I); where: R1 is an amine residue; and R2 and R3 are the same or different and are selected from the group consisting of H, alkyl, and hydroxyalkyl; reacting the hydroxy alkyl urethane modifier with an epoxy silane to form a silane-modified hydroxy alkyl urethane; and reacting the silane-modified hydroxy alkyl urethane with a silyl terminated polyether to form a moisture-cure resin composition. | ||||||
| 184 | IMPROVED ANTIVIRAL COMPOUND WITH UV REFLECTIVITY | PCT/US2021042423 | 2021-07-20 | WO2022020385A1 | 2022-01-27 | BOBLAK KENNETH; SAVOIA CARL; LEE JUE-HYUN; KURUGANTI VIJAYA; WINKLER CREW; BENSON BRIANT; OTTMAN DAVID; DOBBINS MICHAEL |
| A dispenser comprising a dispensing device containing a dispensing device solution, the dispensing device solution comprising C20H29NO7Si, the dispensing device solution having antiviral properties and emitting or reflecting UV light, wherein the dispensing device solution may be used in combination with antimicrobial products, wherein the dispensing device solution further comprises polymerizable UV absorbing and fluorescing elements, wherein the polymerizable UV absorbing and fluorescing elements are biodegradable, water soluble and copolymerize into hydrogel polymers, the dispensing device further comprising a dispensing unit. To verify proper application, a UV light source may directed to the dispensed solution. | ||||||
| 185 | ADDITIVES FOR PRODUCING POLYURETHANES | PCT/US2021031296 | 2021-05-07 | WO2021231212A1 | 2021-11-18 | BEREZHANSKYY YEVGEN; GRAHAM JOLENE CHEREE |
| A foam forming composition is provided. The foam forming composition comprises, as an additive, a bis-carbamate compound, a bis-functional amide compound, or combination of two or more thereof. The compositions are suitable for producing flexible foams. Foams formed from compositions comprising these additives exhibit improved properties including improvement in one or more of tensile strength, tear strength, and/or elongation at break. | ||||||
| 186 | VERWENDUNG OLIGOMERER CARBODIIMIDE ALS STABILISATOREN | PCT/EP2012/054550 | 2012-03-15 | WO2012126797A3 | 2012-09-27 | SMIT, Theo; POTTIE, Laurence; SCHILLO, Simone; FRENZ, Volker; MEER, Roelof van der |
Verwendung oligomerer Carbodiimide enthaltend mindestens eine heterocyclische Endgruppe, als Stabilisatoren für Polymere. Wobei die oligomeren Carbodiimide Verbindungen der allgemeinen Formel (I) sein können, wobei A1, A2 unabhängig voneinander, gleich oder verschieden, Kohlenwasserstoffgruppen mit 2 bis 20 Kohlenstoffatomen, B1, B2 unabhängig voneinander, gleich oder verschieden, Heterocyclen, C1-C30-Alkohole, Poyletherole, Polyesterole, Amine, Polyetheramine, Polyesteramine, Thioalkohole, Polyetherthiole, Polyesterthiole, R1, R2 unabhängig voneinander, gleich oder verschieden, (A), n ganze Zahl im Bereich von 2 bis 100, sind und wobei A1, A2, B1 und B2 jeweils an beliebiger Position durch C1-C20-Alkyl, C2-C20-Alkenyl, C2-C20-Alkinyl, C1-C20-Alkoxy, Carbonyl-Sauerstoff (=O) oder Halogen substituiert sein können, unter der Maßgabe, das mindestens ein Substituent B1 oder B2 eine heterocyclische Endgruppe ist. Weiterhin Verfahren zur Stabilisierung von Polymeren gegen Hydrolyse durch oligomeren Carbodiimide. |
||||||
| 187 | RENIN INHIBITORS | PCT/CA2008/001482 | 2008-08-18 | WO2009023964A1 | 2009-02-26 | JUTEAU, Helene; GALLANT, Michel; DUBE, Daniel; ROY, Patrick; ASPIOTIS, Renee; FORTIN, Rejean; LACOMBE, Patrick; MCKAY, Daniel; WU, Tom, Yao-Hsiang |
The present invention relates to biphenyl compounds of formula (I). These compounds are renin inhibitors of a non- peptidic nature and of low molecular weight. The invention further relates to a pharmaceutical composition containing said compounds, as well as their use and method of treatment of cardiovascular events and renal insufficiency. |
||||||
| 188 | ANTI-CORONAVIRUS COMPOUNDS | PCT/US2005015227 | 2005-05-03 | WO2006073456A3 | 2006-09-14 | WONG CHI-HUEY; WU CHUNG-YI; JAN JIA-TSRONG |
| A method of treating coronavirus infection. The method includes administering to a subject suffering from or being at risk of suffering from such infection an effective amount of a compound of formula (I). Each variable in this formula is defined in the specification. | ||||||
| 189 | CRYSTALS OF LADOSTIGIL TARTRATE, METHODS OF PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREOF | PCT/US2006/006251 | 2006-02-22 | WO2006091656A1 | 2006-08-31 | BAHAR, Eliezer |
Disclosed is crystalline ladostigil tartrate of a specified density, compositions, including pharmaceutical compositions comprising such ladostigil tartrate, and a process for the manufacture thereof. |
||||||
| 190 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | PCT/US2004027330 | 2004-08-20 | WO2005019163A2 | 2005-03-03 | GALLOP MARK A; YAO FENMEI; LUDWIKOW MARIA J; PHAN THU; PENG GE |
| The disclosures herein relate generally to acyloxyalkyl carbamate prodrugs of (±) 4 amino 3 (4 chlorophenyl)butanoic acid and analogs thereof, pharmaceutical compositions thereof , methods of making prodrugs of (±) 4 amino 3 (4 chlorophenyl)butanoic acid and analogs thereof, methods of using prodrugs of (±) 4 amino 3 (4 chlorophenyl)butanoic acid and analogs thereof, and pharmaceutical compositions thereof for treating or preventing common diseases and/or disorders such as spasticity and/or acid reflux disease. The disclosures herein also relate to acyloxyalkyl carbamate prodrugs of (±) 4 amino 3 (4 chlorophenyl)butanoic acid and analogs thereof which are suitable for oral administration and to sustained release oral dosage forms thereof. | ||||||
| 191 | NOVEL GLUCAGON ANTAGONISTS | PCT/DK2003/000903 | 2003-12-18 | WO2004056763A2 | 2004-07-08 | KODRA, Janos, Tibor; BEHRENS, Carsten; MADSEN, Peter; JØRGENSEN, Anker, Steen; CHRISTENSEN, Inge, Thøger |
Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists. |
||||||
| 192 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | PCT/US0218689 | 2002-06-11 | WO02100347A3 | 2003-10-16 | GALLOP MARK A; CUNDY KENNETH C; ZHOU CINDY X; QIU FAYANG G; YAO FENMEI; XIANG JIA-NING; OLLMAN IAN R |
| The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using phannaceutical compositions of prodrugs of GABA analogs for treating or preventing common diseases and/or disorders. | ||||||
| 193 | 2-AMINOTHIAZOLINE DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | PCT/FR2001/001760 | 2001-06-07 | WO01094325A1 | 2001-12-13 | |
| The invention concerns 2-aminithiazoline derivatives of formula (I) wherein: either R1 is a hydrogen atom or an alkyl radical and R2 is an alkyl, -alk-NH2, -CH-R3, -CH2-S-R4 or phenyl radical substituted by a nitro or NH-C(=NH)CH3 radical; or R1 is an alkyl radical and R2 is a hydrogen atom; R3 is a cycloalkyl (3-6C), pyridyl, pyridyl N-oxide, thienyl, thiazolyl, imidazolyl, pyrazinyl, triazolyl, phenyl or phenyl radical substituted by a nitro, hydroxy or carboxy radical; R4 represents a pyridyl or pyridyl N-oxide radical; alk represents an alkylene radical or their pharmaceutically acceptable salts excluding some known compounds, and the use of said derivatives as inducible NO-synthase inhibitors. | ||||||
| 194 | EFFICIENT SYNTHESIS OF ALKYL CARBONATES | PCT/US0004738 | 2000-02-25 | WO0050376A9 | 2001-10-11 | JUNG KYUNG WOON |
| Efficient synthetic methods towards mixed aliphatic carbonates through the three component couplings of aliphatic alcohols, alkyl halides and carbon dioxide in the presence of cesium carbonate and tetrabutylammonium iode (TBAI). Due to their enhanced nucleophilicities, cesium alkoxides are smoothly incorporated into CO2, allowing for mild reaction conditions such as ambient temperatures and short reaction durations. Various primary and secondary substrates are compatible under the standard conditions, offering high yields, while chiral templates such as alpha -hydroxy carbonyls are resistant to racemization. | ||||||
| 195 | EFFICIENT SYNTHESIS OF ALKYL CARBONATES | PCT/US0004738 | 2000-02-25 | WO0050376A3 | 2001-07-05 | JUNG KYUNG WOON |
| Efficient synthetic methods towards mixed aliphatic carbonates through the three component couplings of aliphatic alcohols, alkyl halides and carbon dioxide in the presence of cesium carbonate and tetrabutylammonium iode (TBAI). Due to their enhanced nucleophilicities, cesium alkoxides are smoothly incorporated into CO2, allowing for mild reaction conditions such as ambient temperatures and short reaction durations. Various primary and secondary substrates are compatible under the standard conditions, offering high yields, while chiral templates such as alpha -hydroxy carbonyls are resistant to racemization. | ||||||
| 196 | EFFICIENT SYNTHESIS OF ALKYL CARBONATES | PCT/US2000/004738 | 2000-02-25 | WO00050376A2 | 2000-08-31 | |
| Efficient synthetic methods towards mixed aliphatic carbonates through the three component couplings of aliphatic alcohols, alkyl halides and carbon dioxide in the presence of cesium carbonate and tetrabutylammonium iode (TBAI). Due to their enhanced nucleophilicities, cesium alkoxides are smoothly incorporated into CO2, allowing for mild reaction conditions such as ambient temperatures and short reaction durations. Various primary and secondary substrates are compatible under the standard conditions, offering high yields, while chiral templates such as alpha -hydroxy carbonyls are resistant to racemization. | ||||||
| 197 | AMINOALKYLPHENOL DERIVATIVES AND RELATED COMPOUNDS | PCT/US1998/018587 | 1998-09-04 | WO99016746A1 | 1999-04-08 | |
| Novel aminoalkylphenols, intermediates and processes for the preparation thereof, and methods of relieving memory dysfunction utilizing the aminoalkylphenols or compositions thereof are disclosed. | ||||||
| 198 | MAIN PROTEASE INHIBITORS | PCT/EP2023079898 | 2023-10-26 | WO2024089159A1 | 2024-05-02 | EL OUALID FARID; NIJKERK ALFRED |
| The invention relates to compounds of formula (I) wherein R1, R2, R3 and R4 are as defined herein, pharmaceutical compositions comprising the compounds and methods for synthesising compounds according to formula I. This invention further relates to methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds on the invention and uses of the compounds of the invention in the these methods and in the manufacturing of a medicament. | ||||||
| 199 | EPOXY AMINE (METH)ACRYLATE HYDROXY URETHANE RESIN COMPOSITION | PCT/GB2022051729 | 2022-07-06 | WO2023161597A1 | 2023-08-31 | BARTHEL BERNARD |
| A two-part epoxy resin composition is provided comprising: a first resin part comprising a modified hydroxy alkyl urethane and an epoxy component; and a second resin part comprising an amine component; wherein the modified hydroxy alkyl urethane is formed by a reaction between a (meth)acrylate monomer or oligomer and a hydroxy alkyl urethane having the formula: (Formula (I)); where: R1 is an amine residue; and R2 and R3 are the same or different and are selected from the group consisting of H, alkyl, and hydroxyalkyl. | ||||||
| 200 | BINDING COMPOUND AND USES THEREOF | PCT/GB2017/053205 | 2017-10-24 | WO2018078351A1 | 2018-05-03 | WALKER, Brian; MARTIN, Lorraine; FERGUSON, Timothy |
Described are compounds for targeting proteases, e.g. serine proteases and their use in the diagnostic methods and methods for treatment of respiratory diseases such as cystic fibrosis. The compounds have the structure [H]-[B]-[A]; wherein [H] is a hydrophilic group, [B] is a subsite recognition group and [A] is a binding group; wherein A has the formula: -C(0)-CH2-NR1-COOR2 and wherein [B] has the structure :(i)-[CO-CH2- NR3]m-, or (ii)-[AA1-AA2]- or (iii) -(AA1-C0-CH2NR3)- or (iv) -(CO-CH2-NR3- AA1)- or (v) -(C0-CH2-NR4-AA1-AA3)-. |
||||||
QQ群二维码
意见反馈
意见反馈